Entity > Corporation > US > Bryan Texas > Ibio

About iBio

iBio, Inc. is a biotechnology company that provides contract development and manufacturing services to collaborators and third-party customers in the United States. It is a developer of next-generation biopharmaceuticals and the pioneer of the sustainable FastPharming Manufacturing System ®. The company operates in two segments: Biopharmaceuticals and Bioprocessing.

iBio’s High-Quality Protein Products: Current products include growth factors, cytokines and lectins, as they play an important role in the research and development of various diseases such as cancer and autoimmune diseases. iBio's high-quality proteins can be used for a variety of applications, including SDS-PAGE, ELISA, cell culture supplementation and Western blot. These products are recombinant GNA, recombinant human Flt3L with His tag (Flt3L-His), recombinant human interleukin 6 (IL -6) and recombinant human stem cell factor with His tag (SCF -His).

Pioneering the Next Generation of Biopharmaceuticals using the FastPharming Technology: The FastPharming System is iBio's proprietary approach to producing drugs and proteins in plants. It uses hydroponically grown transiently transfected plants, novel expression vectors, a large-scale transient transfection method and other technologies that can be used to produce complex therapeutic proteins. iBio believes that the FastPharming System will enable biologics production that is faster, less expensive and more environmentally friendly than other approaches.

Operating in Biopharmaceuticals and Bioprocessing Segments: iBio's biopharmaceutical segment is currently focused on developing products using the FastPharming System in the areas of therapeutics (antifibrotics and oncology) and vaccines (COVID -19 and classical swine fever). The Bioprocessing segment, on the other hand, is active in the business areas of services and research and bioprocessing.

Partnerships and Collaboration: iBio, Inc. has a licence agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases, a collaboration agreement with The Texas A&M University System to develop 2019 coronavirus disease vaccine candidates, a licence agreement with the University of Natural Resources and Life Sciences, Vienna, Austria, and a collaboration agreement with CC -Pharming Ltd. The company is headquartered in Bryan, Texas.

Industry: Business & Industrial > Pharmaceuticals & Biotech

More information about iBio

Company Attribute Value
Address StreetAddress: 8800 Hsc Pkwy, AddressLocality: Bryan, AddressRegion: Texas, PostalCode: 77807, AddressCountry: United States
Founding Date 2008
Name iBio
Number Of Employees 105
Revenue $2,383,000 USD
Ticker Symbol NYSE: IBIO
Url ibioinc
Facebook facebook
Linkedin linkedin
Twitter twitter
Google google



Bryan, US
20 Feb 2024

Bryan, US
20 Feb 2024


Page: 1 Desktop | Laptop Devices

https://finance.yahoo.com › quote › IBIO
iBio, Inc. (IBIO) Stock Price, News, Quote & History
iBio, Inc.
https://www.marketwatch.com › ... › Stocks › United States
iBio Inc. Stock Quote (U.S.: NYSE American)
https://www.cnbc.com › quotes › IBIO
Ibio Inc - Stock Price, Quote and News
https://www.nasdaq.com › Market Activity › Stocks
iBio, Inc. Common Stock (IBIO)
Related Searches
Related Searches
ibio rumors
ibio news today
ibio news
Knowledge Panel
Knowledge Panel

iBio, Inc. (Biotechnology company)


  • Stock price : IBIO (NYSEAMERICAN) $1.26 +0.04 (+3.28%)Feb 16, 4:00 PM EST - Disclaimer
  • Headquarters : Newark, DE
  • Founded : 2008

All information on this page is taken from publicly available sources, and the analysis we provide is a representation of Google's search results for the entity and does not represent any opinion or judgement about the entity by Kalicube itself. If you disagree with this analysis, please contact us and cite this reference : 193750